Australia Health

Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline.

Seven Australian startups have secured $15.6 million in non-dilutive federal funding to commercialise dementia diagnostics, therapies, and digital tools.

Genetic Signatures (ASX:GSS) has agreed on commercial terms to acquire Microba Life Sciences (ASX:MAP).

Rhythm Biosciences (ASX:RHY) completed the first phase of its ColoSTAT technology transfer and assessment with a National Health Service laboratory.

Neurotech International (ASX:NTI) has dosed the first patient in its pivotal Phase 3 "Beyond Harmony" clinical trial.

Nyrada (ASX:NYR) has received firm commitments to raise $12 million through a placement of approximately 19.4 million CHESS Depository Instruments.

Telix Pharmaceuticals (ASX:TLX) announced a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valued at US$1.65 billion.

Memphasys (ASX:MEM) signed an exclusive three-year distribution agreement with specialist IVF supplier INVIDO LAB to commercialise its Felix System across the Czech Republic, Slovakia, and Kazakhstan.

Ramsay Santé presented its Connecting Care 2030, targeting annual revenue growth of approximately 3.0% through FY29.

Echo IQ (ASX:EIQ) has commenced work to resolve statistical analysis feedback from the US FDA.

Resonance Health (ASX:RHT) has signed a global strategic alliance and master services agreement with London-headquartered Image Analysis Group.

Biotechnology giant CSL (ASX:CSL) has acknowledged shareholder frustration after a tumultuous year marked by executive changes.